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Résumé en
anglais
Although the existence of atypical femoral fractures is well established and
bisphosphonate therapy is thought to be a major risk factor, the underlying
mechanisms are poorly understood. Epidemiological data show that atypical
femoral fractures account for only a small proportion of diaphyseal subtrochanteric
femoral fractures, being about 100 times less common than proximal femoral
fractures. Consequently, the existence of atypical femoral fractures does not call
into question the extremely favorable risk/benefit ratio of bisphosphonate therapy
in patients with osteoporosis. Clearly, the number of fractures prevented by
bisphosphonate therapy far exceeds the number of atypical femoral fractures
potentially related to bisphosphonates.
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